Contact PD/PI: Kimberly, Robert P The vision of the Center for Clinical and Translational Science (CCTS) Hub is to reduce health disparities in diseases disproportionately represented within the Deep South as we accelerate discovery to improve human health. We have established a robust Partner Network ? spanning Alabama, Mississippi and Louisiana ? to ensure that our research and training efforts serve the special populations in our region while maximizing collaborative synergies in translational research (Aim 1). We promote the continued development of a diverse, multidisciplinary research workforce representing all career stages, by supporting a broad portfolio of NRSA training, mentored career development, content specific educational programs and experiential learning opportunities (Aim 2). These initiatives deepen scientific understanding of clinical and translational science, establish core competencies and advance the knowledge base in good clinical practice, study design, bioethics, conduct of clinical trials and team science. The CCTS supports ethical, scientifically rigorous clinical trials and pilot research across the CCTS Partner Network (Aim 3) through focused efforts to provide resources, specialized services and consultation in genomics, informatics, biostatistics and epidemiology, clinical research, advanced imaging and drug discovery. The CCTS fosters the application of best practices, including those established by the CTSA Consortium, and will promote tools that enable the rapid and efficient execution of multi-site clinical trials, taking advantage of the electronic health record to inform feasibility and access to study populations. Importantly, in keeping with our goal of reducing regional health disparities, we recognize the importance of engaging our communities in the planning and conduct of research (Aim 4). Through our community engagement arm ? One Great Community ? we are expanding programmatic outreach by taking successful community-based participatory research approaches to a regional scale. Finally, we understand the importance of evaluating the activities of the CCTS Partner Network to ensure that we are accomplishing our goals (Aim 5). Didactic programs, community engagement and research processes are evaluated by a panel of tailored and common metrics to guide strategies and outline progress towards achieving defined goals. By achieving these aims, the CCTS Partner Network will accelerate clinical and translational research in the Deep South and advance the amelioration the significant health disparities faced by our populations. Further, the CCTS Hub and its Partner Network will be well-positioned to work with other hubs and the CTSA Consortium in the dissemination of best practices in clinical and translational research and training. Project Summary/Abstract Page 248 Contact PD/PI: Kimberly, Robert P

Public Health Relevance

The UAB Center for Clinical and Translational Science (CCTS) and its regional Partner Network of ten institutions in the Deep South are dedicated to lessening health disparities and the disproportionate burden of disease in our population. We will accomplish these goals by supporting cutting-edge translational research, pursuing novel team science-driven investigation into new therapies and health care delivery paradigms, and developing the next generation of a diverse, highly-trained clinical and translational research workforce to tackle health challenges. Our work will complement and inform national and international translational research efforts to improve public health and well-being. Project Narrative Page 249

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
3UL1TR001417-03S2
Application #
9466306
Study Section
Special Emphasis Panel (ZTR1)
Program Officer
Rosemond, Erica
Project Start
2015-08-18
Project End
2019-03-31
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
3
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Guimbellot, Jennifer S; Acosta, Edward P; Rowe, Steven M (2018) Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer. Pediatr Pulmonol 53:E6-E8
Leavesley, Silas J; Sweat, Brenner; Abbott, Caitlyn et al. (2018) A theoretical-experimental methodology for assessing the sensitivity of biomedical spectral imaging platforms, assays, and analysis methods. J Biophotonics 11:
Roberts, Brian S; Hardigan, Andrew A; Moore, Dianna E et al. (2018) Discovery and Validation of Circulating Biomarkers of Colorectal Adenoma by High-Depth Small RNA Sequencing. Clin Cancer Res 24:2092-2099
Frugé, Andrew D; Ptacek, Travis; Tsuruta, Yuko et al. (2018) Dietary Changes Impact the Gut Microbe Composition in Overweight and Obese Men with Prostate Cancer Undergoing Radical Prostatectomy. J Acad Nutr Diet 118:714-723.e1
Ross, Lesley A; Webb, Christina E; Whitaker, Christine et al. (2018) The Effects of Useful Field of View Training on Brain Activity and Connectivity. J Gerontol B Psychol Sci Soc Sci :
McKenzie, Katelyn A; El Ters, Mirelle; Torres, Vicente E et al. (2018) Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort. BMC Nephrol 19:378
Hunter, Gary R; Plaisance, Eric P; Carter, Stephen J et al. (2018) Why intensity is not a bad word: Optimizing health status at any age. Clin Nutr 37:56-60
Mukerji, Reshmi; Hendrickson, Curtis; Genschmer, Kristopher R et al. (2018) The diversity of the proline-rich domain of pneumococcal surface protein A (PspA): Potential relevance to a broad-spectrum vaccine. Vaccine 36:6834-6843
Olson, Kristin M; Tang, Jianming; Brown, LaDraka' et al. (2018) HLA-DQB1*06 is a risk marker for chlamydia reinfection in African American women. Genes Immun :
Davies, Jane C; Moskowitz, Samuel M; Brown, Cynthia et al. (2018) VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med 379:1599-1611

Showing the most recent 10 out of 355 publications